Trial Profile
A Double-Blind Efficacy and Safety Study of Evacetrapib Followed by an Open-Label Extension in Japanese Patients With Primary Hypercholesterolemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evacetrapib (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 01 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 22 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 10 Mar 2015 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.